610

DRUG3 trials

Sponsors

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Conditions

Asthmaadd-on Maintenance Treatment of Patients With Severe Eosinophilic Asthma

Phase 1

Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.add-on Maintenance Treatment of Patients With Severe Eosinophilic Asthma

Start: 2020-06-12End: 2021-06-01Target: 52Updated: 2021-01-28

Phase 2

A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma

Active, not recruitingNCT06680947

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Asthma

Start: 2024-12-20End: 2027-09-01Target: 225Updated: 2026-01-29

Phase 3

Efficacy and Safety Study of 610 in Patients With Severe Asthma

RecruitingNCT06323213

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Asthma

Start: 2024-06-24End: 2027-09-30Target: 480Updated: 2026-01-07